Aldeyra Therapeutics, Inc.

Aldeyra is headquartered in Lexington, Massachusetts and is incorporated in Delaware, with operations centered in the United States. The company has indicated that reproxalap may require clinical activities and regulatory review outside the United States as well, which suggests some international development exposure even before commercialization. Because it has no approved products, current geographic exposure is driven mainly by where trials are run, where regulators are engaged, and where future partners may be located. If approved, the company would likely commercialize through a partner or direct channel in major ophthalmology markets, but no country-level revenue is currently disclosed.

Aldeyra's most important risk is that reproxalap may not receive approval, may face delays, or may fail commercially even if approved, which would materially impair the business. The company also depends on third parties for clinical trials and likely for future commercialization, so execution failures by CROs, investigators, or partners could delay development and increase costs. As a clinical-stage biotech with no approved products, Aldeyra faces substantial financing risk because it must raise additional capital to fund trials, manufacturing scale-up, and commercialization preparation. More broadly, the company is exposed to intense biotechnology competition, regulatory uncertainty in the U.S. and abroad, and the possibility that prior clinical signals will not be replicated in later studies.